Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data (Q31053321)

28 June 2017

1 reference

title

Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data (English)

1 reference

28 June 2017

0 references

Anders G Olsson

1

1 reference

28 June 2017

1 September 2006

1 reference

Current Atherosclerosis Reports

28 June 2017

1 reference

28 June 2017

8

1 reference

28 June 2017

5

1 reference

28 June 2017

382-389

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-006-0035-7

28 June 2017

0 references

cites work

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-006-0035-7

Apparent discontinuation rates in patients prescribed lipid-lowering drugs.

21 January 2018

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

1 reference

12 December 2020

Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

1 reference

12 December 2020

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

1 reference

12 December 2020

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness

1 reference

12 December 2020

Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

1 reference

12 December 2020

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

1 reference

12 December 2020

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

12 December 2020

Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events

1 reference

12 December 2020

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

1 reference

12 December 2020

Safety of rosuvastatin

1 reference

12 December 2020

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

1 reference

12 December 2020

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators

1 reference

12 December 2020

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

1 reference

12 December 2020

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

12 December 2020

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

12 December 2020

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Withdrawal of statins increases event rates in patients with acute coronary syndromes

1 reference

12 December 2020

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

1 reference

12 December 2020

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

1 reference

12 December 2020

Rosuvastatin-induced arrest in progression of renal disease

1 reference

12 December 2020

A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000.

1 reference

12 December 2020

Adherence in chronic disease

1 reference

12 December 2020

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study

1 reference

12 December 2020

Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis

1 reference

12 December 2020

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

12 December 2020

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

1 reference

12 December 2020

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

12 December 2020

Increased thrombotic vascular events after change of statin

1 reference

12 December 2020

Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)

1 reference

12 December 2020

The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events

1 reference

12 December 2020

Only one of four patients with familial hypercholesterolaemia reach cholesterol treatment goals in primary prevention

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

12 December 2020

Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group

1 reference

12 December 2020

10.1007/S11883-006-0035-7

Identifiers

DOI

1 reference

PubMed ID

16901408

Dimensions Publication ID

28 June 2017

0 references

1 reference

PubMed ID

16901408